BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29061373)

  • 1. Resolution of contradiction between in silico predictions and Ames test results for four pharmaceutically relevant impurities.
    Gunther WC; Kenyon MO; Cheung JR; Dugger RW; Dobo KL
    Regul Toxicol Pharmacol; 2017 Dec; 91():68-76. PubMed ID: 29061373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutagenicity assessment strategy for pharmaceutical intermediates to aid limit setting for occupational exposure.
    Araya S; Lovsin-Barle E; Glowienke S
    Regul Toxicol Pharmacol; 2015 Nov; 73(2):515-20. PubMed ID: 26454093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of 11 in silico models for the prediction of small molecule mutagenicity: role of steric hindrance and electron-withdrawing groups.
    Ford KA; Ryslik G; Chan BK; Lewin-Koh SC; Almeida D; Stokes M; Gomez SR
    Toxicol Mech Methods; 2017 Jan; 27(1):24-35. PubMed ID: 27813437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbamates and ICH M7 classification: Making use of expert knowledge.
    Hemingway R; Fowkes A; Williams RV
    Regul Toxicol Pharmacol; 2017 Jun; 86():392-401. PubMed ID: 28385577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of published DNA reactivity alerts.
    Myden A; Guesne SJ; Cayley A; Williams RV
    Regul Toxicol Pharmacol; 2017 Aug; 88():77-86. PubMed ID: 28549899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutagenicity assessment of two potential impurities in preparations of 5-amino-2,4,6 triiodoisophthalic acid, a key intermediate in the synthesis of the iodinated contrast agent iopamidol.
    Rossi S; Bussi S; Bonafè R; Incardona C; Vurro E; Visigalli M; Buonsanti F; Fretta R
    Mutat Res Genet Toxicol Environ Mutagen; 2024 Jan; 893():503720. PubMed ID: 38272634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Consultancy Activity on In Silico Models for Genotoxic Prediction of Pharmaceutical Impurities.
    Pavan M; Kovarich S; Bassan A; Broccardo L; Yang C; Fioravanzo E
    Methods Mol Biol; 2016; 1425():511-29. PubMed ID: 27311479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and validation of an in silico toxicology model to predict the mutagenic potential of drug impurities.
    Valerio LG; Cross KP
    Toxicol Appl Pharmacol; 2012 May; 260(3):209-21. PubMed ID: 22426359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing best practise in the application of expert review of mutagenicity under ICH M7.
    Barber C; Amberg A; Custer L; Dobo KL; Glowienke S; Van Gompel J; Gutsell S; Harvey J; Honma M; Kenyon MO; Kruhlak N; Muster W; Stavitskaya L; Teasdale A; Vessey J; Wichard J
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):367-77. PubMed ID: 26248005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ames test study designs for nitrosamine mutagenicity testing: qualitative and quantitative analysis of key assay parameters.
    Thomas DN; Wills JW; Tracey H; Baldwin SJ; Burman M; Williams AN; Harte DSG; Buckley RA; Lynch AM
    Mutagenesis; 2024 Mar; 39(2):78-95. PubMed ID: 38112628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities.
    Sutter A; Amberg A; Boyer S; Brigo A; Contrera JF; Custer LL; Dobo KL; Gervais V; Glowienke S; van Gompel J; Greene N; Muster W; Nicolette J; Reddy MV; Thybaud V; Vock E; White AT; Müller L
    Regul Toxicol Pharmacol; 2013 Oct; 67(1):39-52. PubMed ID: 23669331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide bond-forming reagents HOAt and HATU are not mutagenic in the bacterial reverse mutation test.
    Nicolette J; Neft RE; Vanosdol J; Murray J
    Environ Mol Mutagen; 2016 Apr; 57(3):236-40. PubMed ID: 26840011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses.
    Amberg A; Beilke L; Bercu J; Bower D; Brigo A; Cross KP; Custer L; Dobo K; Dowdy E; Ford KA; Glowienke S; Van Gompel J; Harvey J; Hasselgren C; Honma M; Jolly R; Kemper R; Kenyon M; Kruhlak N; Leavitt P; Miller S; Muster W; Nicolette J; Plaper A; Powley M; Quigley DP; Reddy MV; Spirkl HP; Stavitskaya L; Teasdale A; Weiner S; Welch DS; White A; Wichard J; Myatt GJ
    Regul Toxicol Pharmacol; 2016 Jun; 77():13-24. PubMed ID: 26877192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel QSAR model of Salmonella mutagenicity and its application in the safety assessment of drug impurities.
    Valencia A; Prous J; Mora O; Sadrieh N; Valerio LG
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):427-34. PubMed ID: 24090816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of false positive, contaminant-driven mutagenicity in impurities associated with the sotorasib drug substance.
    Coppi A; Davies R; Wegesser T; Ishida K; Karmel J; Han J; Aiello F; Xie Y; Corbett MT; Parsons AT; Monticello TM; Minocherhomji S
    Regul Toxicol Pharmacol; 2022 Jun; 131():105162. PubMed ID: 35331777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transitioning to composite bacterial mutagenicity models in ICH M7 (Q)SAR analyses.
    Landry C; Kim MT; Kruhlak NL; Cross KP; Saiakhov R; Chakravarti S; Stavitskaya L
    Regul Toxicol Pharmacol; 2019 Dec; 109():104488. PubMed ID: 31586682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of quantitative structure-activity relationship (QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames/QSAR International Challenge Project.
    Honma M; Kitazawa A; Cayley A; Williams RV; Barber C; Hanser T; Saiakhov R; Chakravarti S; Myatt GJ; Cross KP; Benfenati E; Raitano G; Mekenyan O; Petkov P; Bossa C; Benigni R; Battistelli CL; Giuliani A; Tcheremenskaia O; DeMeo C; Norinder U; Koga H; Jose C; Jeliazkova N; Kochev N; Paskaleva V; Yang C; Daga PR; Clark RD; Rathman J
    Mutagenesis; 2019 Mar; 34(1):3-16. PubMed ID: 30357358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A practical application of two in silico systems for identification of potentially mutagenic impurities.
    Greene N; Dobo KL; Kenyon MO; Cheung J; Munzner J; Sobol Z; Sluggett G; Zelesky T; Sutter A; Wichard J
    Regul Toxicol Pharmacol; 2015 Jul; 72(2):335-49. PubMed ID: 25980641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of aromatic amines with different purities and different solvent vehicles in the Ames test.
    Harding AP; Popelier PL; Harvey J; Giddings A; Foster G; Kranz M
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):244-50. PubMed ID: 25542092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A promising Ames battery for mutagenicity characterization of new dyes.
    Umbuzeiro GA; Morales DA; Vacchi FI; Albuquerque AF; Szymczyk M; Sui X; Vinueza N; Freeman HS
    Environ Mol Mutagen; 2021 Jan; 62(1):52-65. PubMed ID: 33252143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.